Join the Pre-Exposure Prophylaxis group to help and get support from people like you.
Pre-Exposure Prophylaxis News (Page 2)
Related terms: Pre-Exposure Prophylaxis HIV Infection, PrEP, Reducing Risk of HIV Infection
Mortality Increased for Infants, Under 5s With HIV Receiving Antiretrovirals
THURSDAY, Nov. 30, 2023 – More infants and children aged younger than 5 years with HIV receiving antiretroviral therapy (ART) die compared with those aged 5 years and older receiving ART, according...
2018 to 2021 Saw Increase in HIV PrEP Provision for Adolescents
MONDAY, Oct. 30, 2023 – From 2018 to 2021, there was an increase in HIV preexposure prophylaxis (PrEP) provision among adolescents, especially among male and older adolescents, according to a study...
Daily Oral PrEP Has Highest Preference Ranking Among Young Men
THURSDAY, Oct. 12, 2023 – Daily oral preexposure prophylaxis (PrEP) has the highest preference ranking among young men who have sex with men, according to a study recently published in the Journal...
Despite New Long-Term Options, People Still Prefer Daily PrEP Pill to Prevent HIV
TUESDAY, Oct. 3, 2023 – New ways to deliver drugs that prevent infection with HIV are out there, but many people still prefer the standard daily PrEP pill, a new study shows. “The oral pill is very e...
Beauty Salon-Based Intervention Builds Knowledge of PrEP in Black Women
THURSDAY, Sept. 14, 2023 – A beauty salon-based intervention improves awareness of and trust in preexposure prophylaxis (PrEP) against HIV among Black cisgender women, according to a study published...
Hypertension, Statin Use Increased for Individuals Using TAF for PrEP
THURSDAY, Sept. 14, 2023 – For individuals taking preexposure prophylaxis (PrEP) for preventing HIV infection, tenofovir alafenamide fumarate (TAF) use is associated with higher incident...
USPSTF Reaffirms Recommendation of PrEP for Those at Increased HIV Risk
TUESDAY, Aug. 22, 2023 – The U.S. Preventive Services Task Force (USPSTF) recommends prescription of preexposure prophylaxis (PrEP) with effective antiretroviral therapy for individuals at increased...
U.S. Global AIDS Program Gets New Home
WEDNESDAY, Aug. 2, 2023 – The President's Emergency Program for AIDS Relief (PEPFAR), a program that has long successfully provided relief to people with AIDS around the world, will now be housed...
Gene Could Lower HIV Levels in Some People of African Descent
WEDNESDAY, Aug. 2, 2023 – A newly discovered genetic variant might explain why some people of African ancestry have naturally lower viral loads of HIV, an international team of researchers reports....
Long-Acting, Injected HIV Meds Can Help Tough-to-Treat Patients
WEDNESDAY, July 5, 2023 – For nearly three decades, daily antiretroviral pills have offered patients living with HIV a highly effective way to keep their infection under control. But some patients,...
FDA Approves Apretude (cabotegravir extended-release injectable suspension) for HIV Pre-Exposure Prophylaxis (PrEP)
LONDON--(BUSINESS WIRE) December 20, 2021 --ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. (Pfizer) and Shionogi Limited (Shionogi)...
FDA Approves Descovy (emtricitabine and tenofovir alafenamide) for HIV Pre-Exposure Prophylaxis (PrEP)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 3, 2019-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a pre-exposure prophylaxis (PrEP) in...
FDA Approves Expanded Indication for Truvada (emtricitabine and tenofovir disoproxil fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents
FOSTER CITY, Calif.--(BUSINESS WIRE)--May 15, 2018-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada...
Ask a question
To post your own question to this support group, sign in or create an account.